DHTRF (DRI Healthcare Trust) Accounts Payable

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHTRF DRI Healthcare Trust DHTRF
33 GF Score
Price $12.70
GF Value $13.36
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is DRI Healthcare Trust Accounts Payable?

Accounts Payable does not apply to banks and insurance companies.

DHTRF
33GF Score
DRI Healthcare Trust DHTRF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?

Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued. The current stock price of $12.70 is trading 4.9% below its estimated GF Value™ of $13.36. GuruFocus considers DRI Healthcare Trust to be Fairly Valued.

Key valuation signals for DHTRF:

  • Accounts Payable:
  • GF Value™: $13.36 vs. price of $12.70 (4.9% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DRI Healthcare Trust Business Description

Other Exchanges DHT.UN:CanadaDHT.U:Canada
Address 100 King Street West, 1 First Canadian Place, Suite 6200, Toronto, ON, CAN, M5X 1B8
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score

Get the complete analysis for DHTRF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.70
Price
$13.36
GF Value